Dermata Therapeutics Inc
DRMA
NASDAQ
Biotechnology
$1.46
USD
-0.11 (-7.01%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.31M
Volume 412.3K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-8.37M
TTM
+19.0%
YoY
Operating Cash Flow
$-8.03M
TTM
+26.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.2 | 1.3 | 1.4 | 1.5 | 2.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 1.8 | 1.8 | 1.9 | 1.9 | 3.0 |
Operating Income | -1.8 | -1.8 | -1.9 | -1.9 | -3.0 |
EBITDA | -1.8 | -1.8 | -1.9 | -1.9 | -3.0 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 |
Income Before Income Taxes | -1.7 | -1.7 | -1.9 | -1.8 | -3.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -1.7 | -1.7 | -1.9 | -1.8 | -3.0 |
Consolidated Net Income / Loss | -1.7 | -1.7 | -1.9 | -1.8 | -3.0 |
Net Income Attributable to Common Shareholders | -1.7 | -1.7 | -1.9 | -1.8 | -3.0 |
Basic EPS | -$1.66 | -$1.65 | -$1.64 | -$0.48 | -$0.74 |
Diluted EPS | -$1.66 | -$1.65 | -$1.64 | -$0.48 | -$0.74 |
Basic Shares Outstanding | 1.0M | 1.0M | 1.1M | 3.9M | 4.0M |
Diluted Shares Outstanding | 1.0M | 1.0M | 1.1M | 3.9M | 4.0M |